Strong Revenue Growth
Fourth quarter revenue of $355.2 million, up 9% year-over-year on a GAAP basis and up 10% on a constant currency basis, exceeding expectations.
Record Profitability
Non-GAAP operating profit growth of 30% and operating margin of 19.6%, up 305 basis points year-over-year.
Significant Free Cash Flow
Generated more than $185 million in free cash flow for the year, up 67% from 2023.
Strong Segment Performance
Cardiovascular segment grew by 8% and Endoscopy by 88%. Peripheral Intervention products sales increased by 5.5%.
Successful Integrations
Completed integrations of EndoGastric Solutions and Cook Medical acquisitions ahead of schedule.
Positive Guidance for 2025
Guidance for 2025 includes GAAP net revenue growth of 8% to 10% and a non-GAAP EPS increase of 4% to 7%.